NCT01269593Active, not recruitingEarly phase 1
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- First submitted
- 29 Dec 2010
- Start date
- 1 Dec 2010
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Multiple myeloma
- NCT number
- NCT01269593
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 63
- From 1 Dec 2010 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous allergic reaction to contrast medium.
Other illness
- Hypersensitivity to iodide products.
- Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)
Lab values
- Bilirubin \> 1.5 x institutional upper limit of normal (ULN)
- AST/ALT \>2.5 x ULN
- Albumin \< 2 g/dl
- GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN. Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min.
- Positive serum pregnancy test for females
Other
- Known hyperthyroidism
- Hepatic:
Who the study is looking for
- Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology)
- Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol.
- This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc).
- Age between 18-90
- Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential
- No breast-feeding
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.